Clinical Research Services Turku CRST Oy — Clinical Trial Site

28 Registered trials

7 Currently recruiting

Organisation

Clinical Research Services Turku CRST Oy

Location

Turku, Finland

Identifier

ORG-100037387

Address

Joukahaisenkatu 2 B, 20520, Finland

Departments

.
1101 : Clinical Research Unit (Phase I)
Clinical Research
Clinical Research Services CRST Turku
Clinical Research Services Turku - CRST Oy
Clinical Research Services Turku CRST Oy
Clinical Trials
CRST Oy - Clinical Research Services Turku Oy
CRST Turku
CRST Turku Oy
Department of Oncology and Radiotherapy Turku University Hospital
Dermatology
N/A
NA
Psychiatry
Research

Clinical trials at this site (28)

Search interface

A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into… Not authorised

2022-501644-15-00 Mild Cognitive Impairment due to Alzheimer's Disease Al 4
Phase I, double-blind, randomized, placebo-controlled study investigating the safety, tolerability and concentrations of the study product K… Not authorised

2023-503909-11-00 Ovarian cancer 1
A Phase 2 Study of Obexelimab in Patients with Relapsing Multiple Sclerosis Recruiting

2024-512707-40-00 RELAPSING MULTIPLE SCLEROSIS 4 2024-11-07
A study to learn how safe the study treatment actinium-225-macropa-pelgifatamab (BAY3546828) is, how it affects the body, how it moves into,… Recruiting

2022-502623-22-00 Metastatic castration-resistant prostate cancer 1 2023-09-18
A study to see how a single increasing dose of the oral drug AD-700 affects the ability of a CT scan to detect activated brown fat in health… Recruiting

2025-520584-41-00 Metabolism dysfunction 3 2026-03-10
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520747-32-00 Mild to moderate Alzheimer’s Disease 5 2025-10-29
A study to test the safety and tolerability of Lu AH69593 in adults that are healthy or have narcolepsy. Recruiting

2024-511073-29-00 Narcolepsy 3 2025-06-13
A clinical proof-of-concept study to reduce smoldering inflammation in progressive MS Recruiting

2024-517336-21-00 Progressive multiple sclerosis 4 2025-03-31
A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet Recruiting

2023-506150-21-00 Celiac Disease 4 2024-05-29
A Phase 2a/b study of the efficacy and safety of subcutaneous amlitelimab in adults with non-responsive celiac disease Ended

2024-511213-38-00 Coeliac disease 4 2024-10-15
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder Ended

2023-505892-56-00 Major Depressive Disorder 5 2024-09-30
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 versus Placebo in Participants wit… Ended

2023-506335-15-00 Major Depressive Disorder 5 2024-07-18
Phase I, double-blind, randomized, placebo-controlled study investigating the safety, tolerability and concentrations of the study product K… Ended

2023-503909-11-01 Ovarian cancer 1 2023-10-30
A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe… Ended

2022-501644-15-01 Mild Cognitive Impairment due to Alzheimer's Disease Al 4 2023-09-28
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants Ended

2024-514004-14-00 Alzheimer’s Disease 3 2023-02-23
GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease. Ended

2025-521107-42-00 Alzheimer's Disease 4 2025-11-25
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended

2024-511557-21-00 Major Depressive Disorder (MDD) with Moderate-to-severe 5 2024-11-14
Phase Ib Safety, Tolerability and Pharmacokinetic Study of Subcutaneously Administered HER-096 in Healthy Volunteer Subjects and Patients wi… Ended

2024-512532-30-00 Parkinson’s Disease 3 2024-09-18
EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended

2023-505083-11-01 Alzheimer's Disease 4 2024-05-07
A Study of the Efficacy, Safety, and Tolerability of KAN-101 in Participants With Celiac Disease Ended

2023-507240-37-00 celiac disease 4 2024-04-30
A Phase 1b Study to Characterize the Safety and Tolerability of TEV-53408 in Adults with Celiac Disease Ended

2022-502817-27-00 Celiac disease 3 2024-03-15
A study to test whether BI 456906 helps people living with overweight or obesity who do not have diabetes to lose weight Ended

2022-502529-17-00 Obesity 5 2024-01-18
A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight Ended

2022-502531-18-00 Obesity 5 2024-01-18
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended

2022-501538-44-00 Atopic Dermatitis 5 2023-04-25